

**We Claim:**

1. (original) A method of treating salt-sensitive hypertension in a mammal suffering therefrom, said method comprising the step of administering a therapeutically effective amount of a cyclic nucleotide phosphodiesterase (PDE) inhibitor to said mammal.
2. (original) The method of Claim 1 wherein the PDE is a PDE that preferentially hydrolyzes cAMP.
3. (original) The method of Claim 2 wherein the PDE is PDE4B or PDE4D or both PDE4B and PDE4D.
4. (original) The method of claim 2 wherein the PDE is a renal isoform or splice variant of PDE4B and PDE4D.
5. (currently amended) The method of claim 2 wherein the PDE is PDE4B1 or PDE4D5 or both PDE4B1 and PDE4D5.
6. (original) The method of claim 1 wherein the inhibitor is an inhibitor of PDEs that preferentially hydrolyze cAMP.
7. (original) The method of claim 6 wherein the inhibitor is an inhibitor of PDE4B or PDE4D or both PDE4B and PDE4D.
8. (original) The method of claim 6 wherein the inhibitor is an inhibitor of renal isoforms and splice variants of PDE4B and PDE4D.
9. (currently amended) The method of claim 2 wherein the inhibitor is an inhibitor of PDE4B1 or PDE4D5 or both PDE4B1 and PDE4D5.
10. (original) The method of claim 6 wherein the PDE inhibitor is a 4-substituted - 2-pyrrolidinone.

11. (original) The method of claim 10 wherein the PDE inhibitor is Rolipram (ZK-62711).

12. (original) The method of claim 6 wherein the PDE inhibitor is Rolipram; 4-substituted - 2-pyrrolidinones; N-substituted cis-tetra-hydrophthalazinones; N-substituted cis-hexa-hydrophthalazinones; substituted aminopyridines; L-791943; TVX2706; RP73401 or RS25344.

13. (currently amended) The method of any one of claims 1 - 12 wherein the mammal is human.

14. (currently amended) A pharmaceutical composition for treating salt-sensitive hypertension, comprising a therapeutically-effective amount of a PDE inhibitor and a pharmaceutically-acceptable carrier, diluent ~~or~~ adjuvant.

15. (original) A pharmaceutical composition according to claim 14, wherein the PDE inhibitor is Rolipram; 4-substituted - 2-pyrrolidinones; N-substituted cis-tetra-hydrophthalazinones; N-substituted cis-hexa-hydrophthalazinones; substituted aminopyridines; L-791943; TVX2706; RP73401 or RS25344.

16. (currently amended) A pharmaceutical composition according to ~~claim~~claim 14 wherein the PDE inhibitor inhibits PDE4B or PDE4D or both PDE4B and PDE4D.

17. (currently amended) A pharmaceutical composition according to claim 16 wherein the PDE inhibitor inhibits PDE4B1 or PDE4D5 or both PDE4B1 and PDE4D5.